Home > News > Arrowhead Subsidiary Successful in Small Animal Studies
April 20th, 2005
Arrowhead Subsidiary Successful in Small Animal Studies
Abstract:
Arrowhead Research Corporation announced today that its majority-owned subsidiary, Insert Therapeutics, has released data demonstrating effective anti-cancer results in animal studies of its lead product, IT-101, against various cancers, including pancreatic cancer, colon cancer, breast cancer, lung cancer, and Ewing's Sarcoma, a cancer primarily affecting children and young adults
Source:
businesswire
Bookmark:
| Related Links |
Arrowhead Research Corporation
| Related News Press |
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||